ArticleJournal of neurology2025
Characteristics of intracerebral hemorrhage associated with dual antiplatelet treatment.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- P2Y12 Inhibitors and Mortality in Patients Hospitalized With Intracerebral Hemorrhage.JAMA network open · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiplatelet treatment is associated with hematoma expansion (HE) and poor outcome in intracerebral hemorrhage (ICH). We aimed to describe the characteristics of ICH associated with dual antiplatelet treatment (DAPT), compared with single (SAPT) and no antiplatelet treatment (NAPT).
methodsA retrospective analysis of ICH patients admitted at nine academic stroke centers in Italy, Germany, and China was conducted. The main outcomes of the analysis were HE (hemorrhage growth > 33% and/or > 6 mL) and poor prognosis at 3 months (modified Rankin Scale 4-6). To account for potential confounders we calculated every patients' predicted probability of the outcome of interest, using logistic regression estimates and summarizing the predicted probability as a continuous variable ranging from 0 to 1.
resultsA total of 1644 patients were included, of whom 463 (28.2%) were on SAPT and 25 (1.5%) on DAPT (aspirin plus clopidogrel). DAPT-associated ICH had the highest risk of HE (expressed as mean predicted probability (95% confidence interval, CI): NAPT 0.23 (95% CI 0.23-0.24), SAPT 0.31 (95% CI 0.30-0.32), DAPT 0.42 (95% CI 0.35-0.49), p < 0.001. DAPT patients had also the highest risk of poor outcome: NAPT 0.48 (95% CI 0.47-0.50), SAPT 0.55 (95% CI 0.52.0.57), DAPT 0.70 (95% CI 0.60-0.79), p < 0.001. Among patients on SAPT, the comparison between ICH associated with aspirin (n = 420) and clopidogrel (n = 43) showed similar rates of HE, and poor outcome (all p > 0.1).
conclusionDAPT is associated with higher risk of HE and poor outcome in acute ICH. These findings might inform clinical practice and future trials.
Indexed as
Identifiers
40885840What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.